Amgen Inc.

Eva Kras

Richard L Remmele, Jr

Susan Irene Hershenson

David N Brems

David Brems

Yatin R Gokarn

Richard Louis Remmele

Richard Louis Remmele, Jr

The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use. The invention in these and other respects can be productively applied to a wide variety of proteins and is particularly useful for making and using self-buffering formulations of pharmaceutical proteins for veterinary and medical use, especially, in particular, for the treatment of diseases in human subjects.

Self-buffering antibody formulations

Growing community of inventors

Redmond, WA, United States of America

Eva Kras